Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 7, 2019 and accepted by EDGAR at Nov 7, 2019, 06:59 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $3.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $7.9m | us-gaap:CostOfRevenue |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $10.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $35.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $6.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$12.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$3.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$18.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$15.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $599.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $21.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $40.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $53.7m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $33.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $124.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$70.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-19-060804. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.